Novartis stopped short of saying it has given up on RNA therapeutics entirely, but the company's pullback from the sector hurt several public biotechnology firms whose stocks declined in the US based on statements from the Swiss drug maker.
Novartis said in a statement given to Scrip that the company "decided to significantly reduce our internal drug discovery efforts...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
